Publications

2024
30. Delaney S, Keinänen O, Lam D, Wolfe AL, Hamakubo T, Zeglis BM. Cadherin-17 as a target for the immunoPET of adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2024. https://doi.org/10.1007/s00259-024-06709-7
29. Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, Keinänen O, Carter LM, Lastwika KJ, Lampe PD, Zeglis BM. Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer. Molecular Pharmaceutics. 2024;21(3):1402-13.

2023
28. Keinänen O, Zeglis BM. “Pretargeted Radiopharmaceutical Therapy” in Radiopharmaceutical Therapy (1^st Edition). Editors: Bodei L, Lewis JS, Zeglis BM. Springer, 2023.
27. Delaney S, Rodriguez C, Sarrett SM, Dayts EJ, Zeglis BM, Keinänen O. Unraveling the in vivo fate of inhaled micro- and nanoplastics with PET imaging. Science of The Total Environment. 2023;904:166320.
26. Delaney S, Sebastiano J, Zeglis BM, Keinänen O. Molecular Imaging, Radiochemistry, and Environmental Pollutants. Journal of Nuclear Medicine. 2023;64(8):1179-84. Alavi-Mandell Award recipient (SNMMI)!
25. Keinänen O, Sarrett SM, Delaney S, Rodriguez C, Dayts EJ, Capone E, Sauniere F, Ippoliti R, Sala G,Iacobelli S, Zeglis BM. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET. Molecular Pharmaceutics. 2023;20(6):3241-48.
24. MacPherson DS, Hwang D, Sarrett SM, Keinänen O, Rodriguez C, Rader C, Zeglis BM. Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate. Molecular Pharmaceutics. 2023;20(1):775-82.

2022
23. Rodriguez C, Delaney S, Sarrett SM, Keinänen O, Zeglis BM. Antibody Engineering for Nuclear Imaging and Radioimmunotherapy. Journal of Nuclear Medicine. 2022;63(9):1316-22. Alavi-Mandell Award recipient (SNMMI)!
22. Kunihiro AG, Sarrett SM, Lastwika KJ, Solan JL, Pisarenko T, Keinänen O, Rodriguez C, Taverne LR, Fitzpatrick AL, Li CI, Houghton AM, Zeglis BM, Lampe PD. CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer. Journal of Nuclear Medicine. 2022;63(11):1701-7.
21. Sarrett SM, Rodriguez C, Rymarczyk G, Hosny MM, Keinänen O, Delaney S, Thau S, Krantz BA, Zeglis BM. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates. Bioconjugate Chemistry. 2022;33(9):1750-60.
20. Keinänen O, Nash AG, Sarrett SM, Sarparanta M, Lewis JS, Zeglis BM. “Emerging Radiopharmaceuticals in Clinical Oncology” in Nuclear Oncology – From Pathophysiology to Clinical Applications (3^rd Edition). Editors: Volterrani D, Erba PA, Strauss HW, Mariani G, Larson SM. Springer Cham, 2022.

2021
19. Sarrett SM*, Keinänen O*, Dayts EJ, Dewaele-Le Roi G, Rodriguez C, Carnazza KE, Zeglis BM. Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy. Nature Protocols. 2021;16(7):3348-81. (*equal contribution)
18. Keinänen O*, Dayts EJ, Rodriguez C, Sarrett SM, Brennan JM, Sarparanta M, Zeglis BM*. Harnessing PET to track micro- and nanoplastics in vivo. Scientific Reports. 2021;11(1):11463. (*co-corresponding authors)
17. Sharma SK, Mack KN, Piersigilli A, Pourat J, Edwards KJ, Keinänen O, Jiao MS, Zhao H, White B, Brooks CL, de Stanchina E, Madiyalakan MR, Hollingsworth MA, Radhakrishnan P, Lewis JS, Zeglis BM. ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody. Clinical Cancer Research. 2021;28(5):948-59.
16. Imlimthan S, Khng YC, Keinänen O, Zhang W, Airaksinen AJ, Kostiainen MA, Zeglis BM, Santos HA, Sarparanta M. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma. Small. 2021;17(18):2007705.
15. Sharma SK, Adumeau P, Keinänen O, Sisodiya V, Sarvaiya H, Tchelepi R, Korsen JA, Pourat J, Edwards KJ, Ragupathi A, Hamdy O, Saunders LR, Rudin CM, Poirier JT, Lewis JS, Zeglis BM. Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. Bioconjugate Chemistry. 2021;32(7):1255-62.
14. Xiao G, Annor GK, Fung K, Keinänen O, Zeglis BM, Bargonetti J. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. Molecular Pharmaceutics. 2021;18(1):338-46.

2020
13. Keinänen O, Fung K, Brennan JM, Zia N, Harris M, van Dam E, Biggin C, Hedt A, Stoner J, Donnelly PS, Lewis JS, Zeglis BM. Harnessing ⁶⁴Cu/⁶⁷Cu for a theranostic approach to pretargeted radioimmunotherapy. Proceedings of the National Academy of Sciences. 2020;117(45):28316-27. Publication of the year (FSNM)!
12. Fung K, Sharma SK, Keinänen O, Roche KL, Lewis JS, Zeglis BM. A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer. Molecular Pharmaceutics. 2020;17(8):3140-7.
11. Fung K*, Vivier D*, Keinänen O, Sarbisheh EK, Price EW, Zeglis BM. ⁸⁹Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe. Molecules. 2020;25(10):2315. (*equal contribution)
10. White JM, Keinänen O, Cook BE, Zeglis BM, Gibson HM, Viola NT. Removal of Fc Glycans from [⁸⁹Zr]Zr-DFO-Anti-CD8 Prevents Peripheral Depletion of CD8+ T Cells. Molecular Pharmaceutics. 2020;17(6):2099-108.
9. Goos JACM, Keinänen O, Zeglis BM, Lewis JS. “Radiopharmaceuticals in Oncology” in Handbook of Radiopharmaceuticals – Methodology and Applications (2^nd Edition). Editors: Scott PJH, Kilbourn MR. Wiley, 2020.

2019
8. Keinänen O, Brennan JM, Membreno R, Fung K, Gangangari K, Dayts EJ, Williams CJ, Zeglis BM. Dual Radionuclide Theranostic Pretargeting. Molecular Pharmaceutics. 2019;16(10):4416-21.
7. Imlimthan S, Otaru S, Keinänen O, Correia A, Lintinen K, Santos HA, Airaksinen AJ, Kostiainen MA, Sarparanta M. Radiolabeled Molecular Imaging Probes for the In Vivo Evaluation of Cellulose Nanocrystals for Biomedical Applications. Biomacromolecules. 2019;20(2):674-83.
6. Membreno R, Keinänen O, Cook BE, Tully KM, Fung KC, Lewis JS, Zeglis BM. Towards the Optimization of Click-Mediated Pretargeted Radioimmunotherapy. Molecular Pharmaceutics. 2019;16:674-83.

2018
5. Keinänen O, Partelová D, Alanen O, Antopolsky M, Sarparanta M, Airaksinen AJ. Efficient cartridge purification for producing high molar activity [¹⁸F]fluoro-glycoconjugates via oxime formation. Nuclear Medicine and Biology. 2018;67:27-35.

2017
4. Keinänen O, Fung K, Pourat J, Jallinoja V, Vivier D, Pillarsetty NK, Airaksinen AJ, Lewis JS, Zeglis BM, Sarparanta M. Pretargeting of internalizing trastuzumab and cetuximab with a ¹⁸F-tetrazine tracer in xenograft models. EJNMMI research. 2017;7(1):95.
3. Keinänen O, Mäkilä E, Lindgren R, Virtanen H, Liljenbäck H, Oikonen V, Sarparanta M, Molthoff CF, Windhorst AD, Roivainen A, Salonen J, Airaksinen AJ. Pretargeted PET imaging of trans-cyclooctene modified porous silicon nanoparticles. ACS Omega. 2017;2(1):62-9.

2016
2. Keinänen O, Li XG, Chenna NK, Lumen D, Ott J, Molthoff CF, Sarparanta M, Helariutta K, Vuorinen T, Windhorst AD, Airaksinen AJ. A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET Imaging. ACS Medicinal Chemistry Letters. 2016;7(1):62-6.

2014
1. Yrjölä S, Sarparanta M, Airaksinen AJ, Hytti M, Kauppinen A, Pasonen-Seppänen S, Adinolfi B, Nieri P, Manera C, Keinänen O, Poso A, Nevalainen TJ, Parkkari T. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. European Journal of  Pharmaceutical Sciences. 2014;67C:85-96.